Drug Database
IL

iloprost (CiVi 030 / CIVI030 / Civi 030)

✓ Approved

SERB Pharmaceuticals · PTGIR · 小分子

什么是 iloprost?

iloprost 是一种小分子,由SERB Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名CiVi 030, CIVI030, Civi 030
公司SERB Pharmaceuticals
药物类别小分子
分子靶点PTGIR
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

iloprost 作用于 1 个分子靶点:

PTGIRprostaglandin I2 receptor (IP, PRIPR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

iloprost 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Injury, poisoning and procedural complicationsFrostbite✓ Approved
Vascular disordersRaynaud's phenomenonPhase III
Musculoskeletal and connective tissue disordersSclerodermaPhase III

相关研究文献

PubMedHandchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...2026-11-18

The Adjunctive Role of Intravenous Iloprost in Tamai Zone I-II Digital Replantation: A Retrospective Multicenter Cohort Study.

Karabulut Furkan F, Ahmedov Anvar A, Çiçek Ali Can AC

Microvascular failure remains a major concern after distal digital replantation. This study aimed to evaluate the adjunctive role of intravenous iloprost in patients undergoing Tamai zone I-II digital replantation. This retrospective multicenter cohort study included 57 patients undergoing complete digital replantation between January 2022 and January 2025. Twenty-six patients received the institution-specific postoperative regimen with a 5-day intravenous iloprost infusion, while 31 patients received the same regimen without iloprost. Allocation was based on the temporal implementation of the iloprost protocol and was not randomized. The primary outcome was complete digit survival. Secondary outcomes included bleeding-related parameters, early and delayed complications, functional outcomes, and Hospital Anxiety and Depression Scale scores. Survival was analyzed using Fisher's exact test. Hospital Anxiety and Depression Scale scores were analyzed by analysis of covariance adjusted for age and digit survival status. The complete digit survival occurred in 23/26 patients (88.5%) in the iloprost group and 22/31 (71.0%) in the control group (Fisher's exact p=0.191; crude odds ratio, 3.14; 95% confidence interval, 0.75-13.12). Bloodletting duration, peak activated partial thromboplastin time, hemoglobin decrease, bleeding requiring compression, and iron supplementation were comparable. Early complications were less frequent with iloprost (19.2% vs. 48.4%; p=0.028; odds ratio, 3.94; 95% confidence interval, 1.18-13.11), whereas delayed complications were similar (11.5% vs. 9.7%; p=1.000). Functional and sensory outcomes were comparable. Hospital Anxiety and Depression Scale scores were higher in the iloprost group (10.69±2.17 vs. 5.90±2.39; p<0.001), remaining significant after adjustment (F=99.165, p<0.001). Iloprost was associated with higher observed digit survival and fewer early complications, but the survival difference was not statistically significant. Larger prospective studies are warranted.

PMID 43051235
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Glucuronyl Glucosyloleanolate: A Safe and Potent AI-Discovered Depigmenting Saponin.

Quesnel Yannick Y, Gold Michael M

Saponins are amphiphilic glycosides found in plants. They have long been used in traditional Asian remedies for their anti-inflammatory, protective, and rejuvenating properties. One representative, Glucuronyl Glucosyloleanolate (GGO), was recently discovered using a combination of artificial intelligence and experimental testing as a depigmenting agent. Its safety has been verified in humans during a patch test on 12 volunteers, followed by an HRIPT study on 100 volunteers. Finally, its depigmenting efficacy has been demonstrated after a clinical trial on 60 volunteers. A 48-h patch test was conducted on 12 volunteers using the pure compound.HRIPT: a patch with 0.1% GGO in mineral oil was applied to 100 volunteers repeatedly over 3 weeks. After a 2-week rest, a single patch was applied again to the induction site and to a new, untreated site for the challenge phase.Clinical trial: monocentric blind study of GGO (0.01% weight) versus placebo on a multi-ethnic panel with pigmentation spots. Safety: No skin irritation or adverse effects were observed in the patch test assay confirming the product's excellent safety. On the 100 volunteers, during the induction period, no reaction of irritation was observed after 3 weeks and during the challenge phase, no allergic reaction was observed. Based on these results, GGO demonstrated very good skin compatibility and does not show a sensitizing effect.Efficacy: all subgroups showed significant depigmentation from Day 21 onwards, which continued to increase in a similar manner to that observed with localized depigmentation. After 84 days, the level of depigmentation achieved was 10% on Asian, 14% on Caucasian and North African skin, and 24% on black skin. Dark Pigmentation spots on Asian and Caucasian skin depigmented at a rate 34% faster than the overall skin tone, resulting in their visual fading. Glucuronyl Glucosyloleanolate, identified through AI-enhanced biopharma strategies, shows strong skin-brightening efficacy and safety. It depigments dark spots faster than skin tone brightening in an 84-day clinical trial. Non-irritant and potent at low doses, it promises broad cosmetic and medical applications (melasma). Future investigations should assess its anti-aging and antioxidative potential to broaden its scope of application.

PMID 43047176
阅读全文 →
PubMedBMC pediatrics2026-11-11

Continuous intravenous infusion of vancomycin in preterm neonates: case series from a neonatal intensive care unit.

Tang Kai Lun KL, Chew Khai Shing KS, Leong Jen Jen JJ, Lim Catherine Tze Yinn CTY et al.

There is no standard dosing guideline available for continuous intravenous infusion (cIVI) vancomycin in the neonatal population. Vancomycin administered as cIVI is the current practice in our neonatal intensive care unit. Data from this case series provided preliminary information on dosing range of cIVI vancomycin, serum vancomycin concentration (SVC), microbiological clearance, and incidence of vancomycin-related nephrotoxicity in neonates. Clinical and laboratory data of this retrospective case series were extracted from patient's medical record and therapeutic drug monitoring database. Of the total 36 steady-state SVCs from 15 records analysed, 64% (n = 23) were within a therapeutic range of 15-25 mg/l. Initial SVCs were generally taken within 20-24 h, however, only 20% (n = 3) were within therapeutic range. Loading dose given ranged between 10 and 15 mg/kg, and the mean maintenance dose was 26 ± 6.58 mg/kg/day. Most of the cases (86.7%, n = 13) were targeted treatment for infections which involved Bacillus spp, Coagulase-negative Staphylococcus (CoNS), and methicillin-resistant Staphylococcus aureus (MRSA). Microbiological clearance was achieved in all targeted cases, and no cases of vancomycin-induced acute kidney injury were reported. This indicates vancomycin continuous infusion dosing regime in neonates seems practicable and was not associated with any incidence of nephrotoxicity. NMRR ID: NMRR-17-3502-37577 (IIR).

PMID 43009860
阅读全文 →
PubMedApplied microbiology and biotechnology2026-11-10

Single-use technologies and sustainability by design in biopharma production.

Ottinger Melanie M, Wenk Irina I, Brühlmann Béla B, Junne Stefan S

Sustainability has become a central challenge for the biopharmaceutical industry, which is characterized by resource-intensive manufacturing processes, complex supply chains, and increasing regulatory expectations for environmental transparency. This review examines the role of single-use technologies (SUTs) and sustainability by design (SbD) approaches in improving the environmental performance of modern biomanufacturing systems. While SUTs offer operational advantages such as increased flexibility, faster facility turnaround, and reduced water and energy consumption compared with stainless steel systems, their widespread adoption also raises concerns regarding plastic waste generation and end-of-life management. Survey results from industry stakeholders further indicate increasing awareness of sustainability challenges, but also reveal gaps in knowledge, governance structures, and practical implementation across the value chain. The paper aims to summarize recent developments in environmental assessment, process engineering, and digital bioprocessing to evaluate pathways toward more sustainable production and, at the same time, to identify knowledge gaps that remain. Emphasis is placed on the integration of life cycle assessment (LCA) and quantitative sustainability metrics into early process development, enabling more informed technology selection and design decisions now and in the future. In addition, emerging technological strategies are discussed, including process intensification, continuous and hybrid manufacturing configurations, and advanced process analytical technologies (PATs) that support real-time monitoring and resource-efficient operation. Overall, the findings highlight that an integrated systems perspective is required that combines technological innovation, standardized environmental metrics, and collaborative industry frameworks. Embedding SbD principles early in product and process development can significantly reduce environmental impacts while maintaining regulatory compliance and economic feasibility.

PMID 43004019
阅读全文 →
PubMedThe Lancet. Oncology2026-11-10

Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial.

Li Jiajia J, Yonemori Kan K, Niimi Kaoru K, Nakagawa Satoshi S et al.

Ovarian clear cell carcinoma is a rare but aggressive and biologically distinct subtype of ovarian cancer, in which PIK3CA mutations are common. Advanced ovarian clear cell carcinoma is very difficult to treat, and after failure of platinum-based chemotherapy, therapeutic options are limited. We aimed to evaluate the anti-tumour activity and safety of the PI3Kα inhibitor, risovalisib, for treatment of patients with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma. We conducted a single-arm, phase 2 trial of the PI3Kα inhibitor, risovalisib, in 27 centres in China and 12 centres in Japan. Eligible participants were adult patients (aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1) with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma and one to three lines of previous systemic anti-tumour treatment. Risovalisib was given orally at 40 mg daily in 21-day cycles until disease progression, unacceptable toxicity, or other protocol-defined reasons for discontinuation. The primary endpoint was objective response rate assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumours (version 1.1), among all treated patients with a confirmed PIK3CA hotspot mutation and baseline tumour assessments with measurable lesions per BIRC (efficacy analysis set). The primary endpoint was considered met if the lower 95% CI was greater than 8%. Safety analyses were performed in all patients who received at least one dose of risovalisib (safety analysis set). The trial is registered with ClinicalTrials.gov (NCT05043922) and is ongoing but no longer recruiting patients. Between Oct 6, 2021, and Jan 31, 2024, 93 patients were enrolled and received risovalisib. The median age was 49 years (IQR 43-58), all patients were female, 52 (56%) were from Japan, 41 (44%) were from China, and 63 (68%) had two or more previous lines of therapy. The median duration of follow-up was 14·5 months (IQR 8·6-18·3). The objective response rate was 29 (35% [95% CI 25-46]) of 84 patients in the efficacy analysis set. The most commonly reported grade 3 or worse treatment-related adverse events in 93 patients were rash (30 [32%]), hyperglycaemia (28 [30%]), and decreased weight (7 [8%]). Treatment-related serious adverse events occurred in 36 (39%) patients, the most common being rash (eight [9%]), pneumonitis (six [6%]), and decreased appetite (four [4%]). There were no treatment-related deaths. These results support risovalisib as a potential novel treatment option for PIK3CA-mutated ovarian clear cell carcinoma, a rare yet lethal cancer in dire need of additional treatment options. Combination strategies including risovalisib could also be explored to further increase efficacy observed in this study. Haihe Biopharma.

PMID 43008753
阅读全文 →
PubMedNature reviews. Drug discovery2026-11-08

Decision quality in biopharma portfolio renewal.

Loche Alberto A, Agrawal Gaurav G, Ascher Jan J

PMID 42995239
阅读全文 →

注册免费账户还可查看另外 3324 篇文献

免费注册查看全部文献 →

了解更多iloprost